Rhumbline Advisers Talaris Therapeutics, Inc. Transaction History

Rhumbline Advisers

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$2.68 - $3.22 $6,257 - $7,518	-2,335 Reduced 66.73%	1,164 $3,000
Q2 2023 Aug 08, 2023	SELL	$1.78 - $3.2 $55,042 - $98,953	-30,923 Reduced 89.83%	3,499 $10,000
Q1 2023 May 11, 2023	BUY	$1.09 - $2.09 $218 - $418	200 Added 0.58%	34,422 $65,000
Q4 2022 Feb 14, 2023	BUY	$0.94 - $1.64 $540 - $943	575 Added 1.71%	34,222 $35,000
Q3 2022 Nov 10, 2022	BUY	$2.3 - $5.03 $4,448 - $9,728	1,934 Added 6.1%	33,647 $88,000
Q2 2022 Aug 11, 2022	BUY	$4.51 - $9.85 $75,641 - $165,204	16,772 Added 112.25%	31,713 $143,000
Q1 2022 May 12, 2022	BUY	$6.89 - $16.56 $4,388 - $10,548	637 Added 4.45%	14,941 $147,000
Q4 2021 Feb 10, 2022	BUY	$12.18 - $17.0 $174,222 - $243,168	14,304 New	14,304 $219,000

75.7K

Ticker TALS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,995,900
Market Cap $109M
Description
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, an...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.